Basilea Pharmaceutica AG Share Price OTC Markets

Equities

BPMUF

CH0011432447

Biotechnology & Medical Research

Market Closed - OTC Markets 18:51:48 20/05/2024 BST 5-day change 1st Jan Change
48.15 USD +8.32% Intraday chart for Basilea Pharmaceutica AG -.--% +17.44%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 182M 203M 15.94B Sales 2025 * 206M 229M 18.04B Capitalization 509M 568M 44.69B
Net income 2024 * 23M 25.64M 2.02B Net income 2025 * 35M 39.02M 3.07B EV / Sales 2024 * 3.12 x
Net Debt 2024 * 57.88M 64.53M 5.08B Net Debt 2025 * 12.51M 13.94M 1.1B EV / Sales 2025 * 2.54 x
P/E ratio 2024 *
21.2 x
P/E ratio 2025 *
17.9 x
Employees 147
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.61%
More Fundamentals * Assessed data
Dynamic Chart
1 day+8.32%
1 month+8.32%
3 months+18.16%
6 months+17.44%
Current year+17.44%
More quotes
1 month
48.15
Extreme 48.15
48.15
Current year
38.60
Extreme 38.6
48.15
1 year
38.60
Extreme 38.6
48.15
3 years
38.60
Extreme 38.6
52.00
5 years
36.59
Extreme 36.59
61.00
10 years
36.59
Extreme 36.59
142.33
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 31/08/14
Director of Finance/CFO 50 31/12/08
Chief Tech/Sci/R&D Officer 60 30/04/18
Members of the board TitleAgeSince
Director/Board Member 71 26/04/17
Director/Board Member 66 31/12/21
Director/Board Member 69 08/04/13
More insiders
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
42.2 CHF
Average target price
70.58 CHF
Spread / Average Target
+67.26%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW